Peptide Schedule Research TeamReviewed Apr 20264 Citations
Adjust vial, water, and dose — answer updates live
on a U-100 syringe for a 200mcg dose
Never miss a dose — 200mcg daily, draw 8.0 units on U-100 syringe.
No signup required to use calculator
Sync to any calendar app
VIP (Vasoactive Intestinal Peptide) is the final step in the Shoemaker CIRS protocol, used intranasally at 200 to 400 mcg per day. Community reports from thousands of patients describe brain fog resolution and biomarker normalization. Formal trials remain limited to Shoemaker's own publications.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 200mcg | 2x Daily |
| Aggressive | 400mcg | Daily |
Your first VIP vial comes as a nasal spray, not an injectable. Standard compounding: 5 mg vial reconstituted in 10 mL bacteriostatic water gives 500 mcg/mL. Each spray actuation delivers 0.1 mL, which equals 50 mcg per spray. Four sprays per dose means 200 mcg total. The biggest mistake people make is starting VIP too early. MARCoNS must be eradicated and confirmed negative on retest. VCS must be passing. If you skip those prerequisites, you'll spend $189 to $399 per month on a peptide that won't work because the underlying inflammation source is still active. Alternate nostrils with each spray (two sprays per nostril per dose). Morning dosing before food is standard. If you're sensitive, ask your prescriber about a 1:10 or 1:100 dilution for the first week; that dilution step makes initiation worsening much less likely. Get fasting lipase drawn before you start. No exceptions. Monthly lipase for three months after that.
Dosing based on Shoemaker CIRS protocol: 200 mcg intranasal 2x/day (clinical practice) — 6 published references.View all sources →
Cross-check your VIP (Vasoactive Intestinal Peptide) reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.